Skip to main content

AdBIOPRO partner Cellevate and Max Planck Society into collaboration for viral vaccine production

Published Jul 11, 2023

Swedish biotech company Cellevate has partnered with the Max Planck Society's Max Planck Institute for Dynamics of Complex Technical Systems in Germany.

The collaboration aims to research and optimize the use of Cellevat3d™ carriers in vaccine production, with a focus on identifying suitable carrier formats and bioreactors. The CEO of Cellevate sees this collaboration as a significant opportunity to enter the lucrative vaccines market. Cellevate's Cellevat3d™ carriers, based on a nanofiber-based platform, are designed for large-scale production of cell lines and biological therapies, and are set to launch commercially in 2024.